Pfizer (XSWX:PFE) Short-Term Debt: CHF3,063 Mil (As of Mar. 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
69 GF Score
Price CHF19.58
GF Value CHF20.75
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Short-Term Debt?

Pfizer XSWX:PFE 69 Short-Term Debt is CHF3,063 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 69/100 and a GF Value™ of CHF20.75 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Short-Term Debt for the quarter that ended in Mar. 2026 was CHF3,063 Mil.

Pfizer's quarterly Short-Term Debt declined from Sep. 2025 (CHF3,426 Mil) to Dec. 2025 (CHF2,513 Mil) but then increased from Dec. 2025 (CHF2,513 Mil) to Mar. 2026 (CHF3,063 Mil).

Pfizer's annual Short-Term Debt declined from Dec. 2023 (CHF8,947 Mil) to Dec. 2024 (CHF6,193 Mil) and declined from Dec. 2024 (CHF6,193 Mil) to Dec. 2025 (CHF2,513 Mil).

Pfizer Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Pfizer Short-Term Debt Related Terms

Pfizer Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Pfizer's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Short-Term Debt Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,063.96 2,733.31 8,947.22 6,193.05 2,513.42

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,950.58 3,493.51 3,425.62 2,513.42 3,062.60
XSWX:PFE
69GF Score
Pfizer Inc XSWX:PFE
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of CHF3,063 Mil mean?
Pfizer (XSWX:PFE) has a Short-Term Debt of CHF3,063 Mil as of Mar. 2026.
Is Pfizer's Short-Term Debt too high?
Pfizer's current Short-Term Debt is CHF3,063 Mil. Overall, Pfizer has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Short-Term Debt compare to GILD and BMY?
Pfizer's Short-Term Debt of CHF3,063 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Pfizer's current Short-Term Debt is CHF3,063 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF20.75, compared to a current price of CHF19.58 — trading 5.6% below its estimated fair value. The current Short-Term Debt is CHF3,063 Mil. Pfizer's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Short-Term Debt is CHF3,063 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.58 is trading 5.6% below its estimated GF Value™ of CHF20.75. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Short-Term Debt: CHF3,063 Mil
  • GF Value™: CHF20.75 vs. price of CHF19.58 (5.6% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
69GF Score

Get the complete analysis for XSWX:PFE

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.58
Price
CHF20.75
GF Value